Since the development of antimicrobial therapy for endocarditis, the need has existed for an in vitro test which would predict therapeutic efficacy. A serum inhibitory assay was first described by Schlichter in 1947 (10, 11) and was later modified to a serum bactericidal assay (the serum killing level [SKL] assay) as the importance of bacterial killing became recognized. As currently performed, dilutions of serum receiving the same inoculum are subcultured after 18 to 24 h of incubation to determine the highest dilution in which .99.9% of the inoculum has been killed. A peak SKL of 1:8 or greater is generally accepted as being predictive of adequate therapy, although this remains to be firmly established in clinical studies (2). Stratton et al. (13) have shown that the SKL is a reasonable measure of the magnitude of antibiotic concentration in serum relative to the minimum bactericidal concentration (MBC) of the infecting organism.
Since the development of antimicrobial therapy for endocarditis, the need has existed for an in vitro test which would predict therapeutic efficacy. A serum inhibitory assay was first described by Schlichter in 1947 (10, 11) and was later modified to a serum bactericidal assay (the serum killing level [SKL] assay) as the importance of bacterial killing became recognized. As currently performed, dilutions of serum receiving the same inoculum are subcultured after 18 to 24 h of incubation to determine the highest dilution in which .99.9% of the inoculum has been killed. A peak SKL of 1:8 or greater is generally accepted as being predictive of adequate therapy, although this remains to be firmly established in clinical studies (2) . Stratton et al. (13) have shown that the SKL is a reasonable measure of the magnitude of antibiotic concentration in serum relative to the minimum bactericidal concentration (MBC) of the infecting organism.
Studies of penicillin-aminoglycoside synergy in experimental endocarditis suggest that the rate of bacterial killing is an important determinant of antibiotic efficacy (4, 9) . This parameter of antibiotic activity is not well demonstrated by the SKL assay. As organisms are quantitated only once during the assay, 18 to 24 h after inoculation, it is the cumulative bactericidal activity, rather than the kinetics of bactepial killing, that is measured.
In an adaptation of an assay suggested by Kunin ( Susceptibility tests. Minimum inhibitory concentrations and MBCs of nafcillin, tobramycin, and gentamicin were determined by standard macrobroth dilution techniques (1) . Synergy studies were performed by the time-kill method in Mueller-Hinton broth (MHB). Portions (0.1 ml) of an overnight culture were added to 10 ml of MHB containing one of the following: nafcillin, 10 ,ug/ml; tobramycin, 1.0 ,ug/ml; gentamicin, 1.0 ,ug/ml; nafcillin, 10 p.g/ml, plus tobramycin, 1.0 ,ug/ml; nafcillin, 10 pLg/ml, plus gentamicin, 1.0 ,ug/ml; or no antibiotic. Cultures were incubated at 35°C for 24 h without shaking. Samples (0.1 ml) were removed from each flask at 6 and 24 h of incubation and quantitatively cultured.
Animal studies. Endocarditis was established in 64 2-to 3-kg white New Zealand rabbits by previously described methods (9) . A polyethylene catheter was inserted through the carotid artery into the left ventricle of the heart and secured in place while the rabbits were under pentobarbital anesthesia. One hour after the insertion of the catheters, 106 CFU of S. aureus in 654 DRAKE, HACKBARTH, AND SANDE 1 ml of saline from an overnight culture was injected via the catheters. Administration of nafcillin (200 mg/kg) was begun 24 h after infection, alone or in combination with either tobramycin or gentamicin (3.4 mg/kg) intramuscularly, and was repeated every 8 h for a total of seven doses. Control animals included in each experiment received no injections. Sixteen hours after the last drug dose, animals were sacrificed by intravenous injection of 125 mg of pentobarbital. The hearts were removed, and vegetations on the aortic valve were excised, weighed, homogenized in 2.5 ml of sterile saline, and quantitatively cultured. Bacterial titers in the vegetations were expressed as CFU per gram of wet vegetation. The lowest concentrations detectable ranged from log1o 2.3 to 3.4, depending on the vegetation weight. Sixteen animals had negative blood cultures at the start of therapy and were excluded from the analysis of results.
Serum antibiotic concentrations, SKL assay, and SBR assay. Blood was obtained from ear arteries 30 to 60 min and 7 to 8 h after dosing, usually after the first or third dose. Serum was removed and stored at -70°C until use. Antibiotic concentration, SKL, and SBR were determined for each specimen, unless testing was limited by the volume of serum obtained. Serum antibiotic concentrations were determined by the agar well diffusion technique, with a Bacillus globigii strain as the indicator organism. When samples contained both an aminoglycoside and nafcillin, either the aminoglycoside was eliminated by adding cellulose phosphate (12) or the beta-lactam was hydrolyzed by adding beta-lactamase (8) .
SKLs were determined by standard techniques (1) with inocula of ca. 5 x 105 CFU/ml from an overnight culture. Dilutions were made in pooled serum obtained from healthy rabbits. Tubes were vortexed immediately after inoculation and againjust before sampling after 24 h of incubation without shaking. Duplicate assays with dilutions prepared in MHB were performed with some samples. The SKL was defined as the greatest dilution in which 99.9o of the inoculum was killed after 24 h of incubation.
SBRs were determined by adding 0.5 ml of inoculum (5 x 105 CFU/ml) from an overnight culture in MHB to 0. Efficacy of therapy in animals. Nafcillin alone reduced vegetation titers below the levels found in untreated control animals (Fig. 1) , and the addition of an aminoglycoside improved the efficacy even further. Control rabbits survived an average of 2.4 days (range of 1 to 4 days) and had mean bacterial concentrations (±1 standard deviation) in vegetations of 8.9 ± 0.8 loglo CFU/g at autopsy. In contrast, rabbits treated with nafcillin had mean concentrations of 5.4 ± 1.6 loglo CFU/g. The addition of tobramycin or gentamicin to nafcillin reduced the titers to 3.9 ± 1.0 loglo and 3.8 ± 1.3 loglo CFU/g, respectively (P < 0.05 for both). Survival was greater than 90% in all treatment groups. These in vivo findings correlated well with the equal potentiation of bacterial killing rates by each aminoglycoside in vitro. Peak antibiotic levels in serum were comparable to those expected to be achieved in man (5) . The mean (± standard deviation) peak concentrations were: nafcillin, 32.2 ± 18.2 ,ug/ml; tobramycin, 6.3 ± 2.3 p,g/ml; and gentamicin, 5.9 ± 1.7 ,.g/ml.
SKLs. The SKLs did not reflect the differences in in vivo efficacy between the antibiotic regimens (Fig. 2) . No significant increase in SKLs was found when either aminoglycoside was combined with nafcillin, despite improved in vivo efficacy. SKLs nafcillin plus gentamicin, and 1:2 to 1:64 (median 1:16) with nafcillin plus tobramycin. Extensive overlap was present among all three treatment groups. Determination of SKLs with broth dilutions rather than serum gave slightly higher SKLs for all three treatment groups but did not -ffect the degree of overlap. Median SKLs of trough samples were 1:2 for all three treatment groups.
SBRs. Eight-hour time-kill curves in peak serum samples diluted 1:2 with an inoculum in MHB reflected the enhanced efficacy of combination therapy (Fig. 3) . Killing was more rapid and of greater magnitude in samples from rabbits receiving an aminoglycoside plus nafciilin, with little or no overlap in the cumulative drop of log CFU between samples from single and combined drug regimens at 4 to 8 h of incubation. Presence of an aminoglycoside produced marked killing in the initial 2 h (-1.0 log10 CFU/h) and less rapid killing in the subsequent 6 h (-0.6 to -0.7 logl0 CFU/h). These rates were significantly higher than those with nafcillin alone, which were -0.3 log10 CFU/h during both the initial 2 and subsequent 6 h. Much greater intersample variability was observed among samples containing an aminoglycoside. Although the differences in SBR results were significant when single and combined drug regimens were compared, within a given treatment regimen, serum samples with the most rapid killing did not necessarily correlate with the lowest vegetations titers. Serum killing curves of trough samples showed no difference between treatment groups. All were comparable to those In this study, the validity of the SKL assay as a measure of adequate therapy is not questioned, but rather its ability to reflect optimal therapy of S. aureus endocarditis, which it fails to do. The SBR assay is proposed as a useful adjunctive test to aid in this determination. It is, simply, an abbreviated time-kill study performed with the bacterial isolate and serum of the individual being treated. The assay is a modification of one suggested by Kunin (7), which has the particular value of measuring the relative antibiotic killing rate. Though no prior studies have specifically examined SKLs in a comparison of single and combination therapies, Durack noted that SKLs were no different in animals receiving penicillin than in those receiving penicillin plus streptomycin during treatment of Streptococcus sanguis endocarditis, despite a marked difference in efficacy between the two treatment regimens (4) . In a clinical study of S. aureus endocarditis, addition of gentamicin to nafcilfin increased the rapidity of bloodstream sterilization, but peak SKLs were similar for both treatment groups (6) .
This study documents the improved efficacy of combined nafcillin-aminoglycoside regimens over those with nafcillin alone in the therapy of experimental S. aureus endocarditis. Peak or trough SKLs do not reflect this enhanced activity, whereas peak SBRs do. The explanation lies in the fact that enhancement of nafcillin activity occurs rapidly and is dependent on aminoglycoside concentration. Sequential culturing of SKL dilutions at 2, 8, and 24 h demonstrated that the enhanced rate of killing by sera containing aminoglycosides occurred only at lower dilutions, usually 1:8 or less, and was evident only at the 2-and 8-h sampling times (data not shown). The killing effect of the aminoglycoside is concentration dependent, i.e., the rate at which the drug kills S. aureus increases with increasing concentrations over the therapeutic range. This is not, however, true of nafcillin, which reaches a maximum rate of bacterial killing at a relatively low concentration (the MBC, which usually is far below the levels generally obtained in serum). Therefore, the maximum SBR will occur with the highest aminoglycoside concentrations (a 1:2 dilution of serum (14) . The assay used resembles that reported here, although the killing curves were obtained with a 1:8 rather than a 1:2 dilution of serum. A 1:2 dilution is preferable since alterations in concentrationdependent effects of the drugs are minimized. The other accepted laboratory tests that evaluate drug interactions (checkerboard and time-kill kinetic studies) are also limited. Although they may effectively predict drug-to-drug interactions, neither reflects accurately the actual drug concentrations in the individual patient or the influence of serum on the results.
Our results, which support the value of the SBR assay, are specifically applicable for combined nafcillin-plus-aminoglycoside therapy of endocarditis caused by methicillin-susceptible S. aureus. Although only a single strain was tested in this study, it is typical of numerous S. aureus strains that we have examined in vitro for aminoglycoside enhancement of nafcillin activity. Whether or not the SBR assay will predict the relative effectiveness for a variety of single antibiotics or significantly different dosage schedules has yet to be studied. Also, the actual rate of eradication of bacteria from vegetations in vivo is far slower than that observed in the SBR assay; this is possibly related to the demonstrated metabolic inactivity of organisms in established vegetations (3) . Evidence for the predictive utility of the SBR assay, as for any in vitro test, must be strictly empirical until the mechanisms of bacterial killing in vivo are elucidated.
The SBR assay could easily be adapted for the clinical microbiology laboratory. With limited sampling times (e.g., 0, 2 to 4, and 6 to 8 h only), the assay would be simple to perform in conjunction with the SKL assay, with final results available the following day. The potential therapeutic value of this test would be to assure the physician that (i) the choice of antimicrobial agents is, in fact, producing a rapid bactericidal effect in vivo, and (ii) the addition of another drug to the regimen increases, rather than decreases, the bactericidal rate. The SKL assay alone cannot reliably provide this guidance. The unique properties of the SBR assay warrant its further evaluation, both in experimental and clinical settings, for infections where rapid eradication of bacteria would be expected to favorably influence the outcome.
